- Business Wire•23 hours agoSeattle Genetics Demonstrates Commitment to Improve Hodgkin Lymphoma Treatment Paradigm through Multiple ADCETRIS® (Brentuximab Vedotin) Data Presentations at ISHL 2016
Seattle Genetics, Inc. today highlighted multiple data presentations at the 10th International Symposium on Hodgkin Lymphoma taking place in Cologne, Germany, October 22-25, 2016, evaluating ADCETRIS across a broad range of Hodgkin lymphoma disease settings.
- American City Business Journals•4 days ago
Seattle Genetics has promoted Dr. Vaughn Himes to the new role of chief technical officer and Dr. Dennis Benjamin to senior vice president, translational research. The Bothell-based biotech firm also announced the appointment of Dr. Robert Lechleider as senior vice president, clinical development. Himes has been with Seattle Genetics (SGEN) since 2009.
- Capital Cube•4 days agoSeattle Genetics, Inc. breached its 50 day moving average in a Bearish Manner : SGEN-US : October 17, 2016
Categories: ETFs Yahoo Finance Click here to see latest analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Seattle Genetics, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving ... Read more (Read more...)
Seattle Genetics, Inc. (SGEN)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
|Bid||16.65 x 200|
|Day's Range||51.12 - 52.00|
|52wk Range||26.02 - 57.83|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||-67.53|
|Avg Vol (3m)||814,389|
|Dividend & Yield||N/A (N/A)|